CVMG-01(CVMG-01) - 药物靶点：AchRab_专利_临床

概要

基本信息

药物类型

治疗性疫苗

别名

Myasterix

靶点

AchRab

作用方式

抑制剂

作用机制

AchRab抑制剂

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [1]

在研适应症-

非在研适应症

重症肌无力

原研机构

Curavac, Inc.

在研机构-

非在研机构

Curavac, Inc.

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 1098881734

Sequence Code 1098881784

关联

2

项与 CVMG-01 相关的临床试验

NCT03165435

/ Withdrawn临床2/3期

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis.

Study CV-0003 will be the second clinical trial administering CV-MG01 in humans. This will be a phase 2/3 proof-of-efficacy therapeutic confirmatory study following the proof-of-concept exploratory phase 1 study (CV-0002).

开始日期2018-07-01

申办/合作机构

Curavac, Inc.

[+2]

NCT02609022

/ Completed临床1/2期

A First-in-human and Proof-of-concept Study to Assess the Safety, Tolerability and Immunogenic Response of CV-MG01, Acetylcholine Receptor Mimetic Peptides, as Potential Therapeutic Vaccine, in Patients With Myasthenia Gravis

Study CV-0002 is the first clinical trial administering CV-MG01 in humans. This clinical trial is a safety and proof-of-concept study (proof of mechanism of action) intended to assess the safety, tolerability and immunogenic response following 3 subcutaneous injections of CV-MG01 as a potential therapeutic vaccine / active immunotherapy in myasthenia gravis (MG) patients.

开始日期2016-03-01

申办/合作机构

Curavac, Inc.

[+3]

100 项与 CVMG-01 相关的临床结果

登录后查看更多信息

100 项与 CVMG-01 相关的转化医学

登录后查看更多信息

100 项与 CVMG-01 相关的专利（医药）

登录后查看更多信息

100 项与 CVMG-01 相关的药物交易

登录后查看更多信息